Emerging Therapies in Lung Cancer: A Review on Targeted and Immune Based Interventions. (PubMed, Curr Drug Discov Technol) - Sep 9, 2026 - "In genetically defined NSCLC subsets, targeted therapies such as Osimertinib and Lorlatinib have significantly enhanced progression-free survival. Similarly, immune checkpoint inhibitors like Nivolumab have redefined care standards, particularly in PD-L1-positive tumours...This article also reviews pivotal clinical trials and newly filed patents, reflecting current and emerging commercial interests. The integration of molecular diagnostics and precision therapies is reshaping lung cancer treatment, with prospective directions aiming to overcome resistance and broaden access to innovative therapies worldwide, including from India and other developing regions."
IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR
|
|
E Bhargav; K C Geervani; Kalpi Sania Kausar; Mulla Shaikshavali; Penugonda Shivarani; Repollu Maddileti; Teleke Kumar Swamy
|